Megan Januska, ATS 2018 – Nontuberculous mycobacteria (NTM) and chronic cough in children
Megan Januska (Icahn School of Medicine at Mount Sinai, New York, NY, US) discusses the background and findings of her presentation entitled: Nontuberculous Mycobacteria and Chronic Cough in Children: An Underappreciated Entity? (abstract available here).
1. What is the typical clinical presentation of nontuberculous mycobacterial (NTM) infections in children? (0:11)
2. Why is NTM infection rarely considered in children presenting with chronic cough? (0:33)
3. Could you tell us a little about the cases you are presenting? (0:52)
4. What is the recommended treatment for NTM infections in children? (1:30)
5. What further studies are needed to optimise the diagnosis and treatment of NTM infections in children? (1:58)
Speaker disclosure: Megan Januska has nothing to disclose in relation to this video interview.
Filmed at the American Thoracic Society (ATS) International Conference 2018, San Diego, CA, US, May 2018.
Share this Video
Related Videos In Paediatric Respiratory Medicine
Theresa W Guilbert, AAAAI 2023: The VOYAGE study: Impact of exacerbation history on dupilumab efficacy in children with asthma
Dupilumab is indicated as an add-on maintenance treatment in children aged 6 years and older with asthma, and demonstrated clinical efficacy in the pivotal VOYAGE study (NCT0294895). We caught up with Dr Theresa W Guilbert (Cincinnati Children’s Hospital & Medical Center; University of Cincinnati, Cincinnati, OH, USA) to discuss the main findings from a post-hoc […]
Theresa W Guilbert, AAAAI 2023: Health and economic burden of asthma exacerbations in children
touchRESPIRATORY were delighted to speak with Dr Theresa W Guilbert (Cincinnati Children’s Hospital & Medical Center; University of Cincinnati, Cincinnati, OH, USA) about the health and economic burden of asthma exacerbations in children, and the limitations of current therapeutic options for children with asthma. The abstract ‘Impact Of Exacerbation History On Dupilumab Efficacy In Children […]
Robin Deterding, ERS 2022: Findings from the InPedILD Trial
The InPedILD trial was a phase 3, double-blind placebo-controlled trial investigating nintedanib in children and adolescents with fibrosing interstitial lung diseases (ClinicalTrials.gov: NCT04093024). We were delighted to speak to Dr. Robin Deterding (University of Colorado; Children’s Hospital Colorado, Aurora, CO, USA) to discuss the aims, design, eligibility criteria and findings from the phase 3 study. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!